NCT05286567View on ClinicalTrials.gov

A Double-blind Placebo-controlled Randomized Trial Evaluating the Efficacy and Safety of a Novel HSP90 Inhibitor (RGRN-305) in the Treatment of Moderate to Severe Hidradenitis Supppurativa.

PHASE1CompletedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

September 1, 2021

Primary Completion Date

August 29, 2022

Study Completion Date

August 29, 2022

Conditions
Hidradenitis Suppurativa
Interventions
DRUG

RGRN-305

Heat shock protein 90 inhibitor

DRUG

Placebo

Placebo (blinded)

Trial Locations (1)

8200

Aarhus University Hospital, Aarhus

All Listed Sponsors
lead

Aarhus University Hospital

OTHER

NCT05286567 - A Double-blind Placebo-controlled Randomized Trial Evaluating the Efficacy and Safety of a Novel HSP90 Inhibitor (RGRN-305) in the Treatment of Moderate to Severe Hidradenitis Supppurativa. | Biotech Hunter | Biotech Hunter